Search results for "Highlights"
Treatment deintensification uncommon in type 2 diabetes
Less than a quarter of patients with an HbA1c below 6.0% had a drug discontinued or a dosage decreased, even after the American Diabetes Association issued a practice advisory about the risk of mortality associated with intensive glucose control.
https://diabetes.acponline.org/archives/2017/05/12/2.htm
12 May 2017
Intensive BP control associated with worse CV outcomes in type 2 diabetes and recent ACS
A post hoc analysis found that patients with baseline systolic blood pressure (BP) <120 mm Hg or >160 mm Hg or follow-up BP <130 mm Hg had a significantly increased risk for a composite outcome of death from cardiovascular (CV) causes, nonfatal myocardial infarction, and nonfatal stroke.
https://diabetes.acponline.org/archives/2018/11/09/1.htm
9 Nov 2018
Spotlight on diabetes incidence and complications
Mortality and cardiovascular complications from diabetes have gone down, but incidence rates among youth are up, according to recent studies of Swedish and American patients, respectively.
https://diabetes.acponline.org/archives/2017/04/14/5.htm
14 Apr 2017
One-hour glucose tolerance test outperforms two-hour test for predicting progression to diabetes
Machine learning was used to combine different variables, including clinical risk factors, plasma glucose and insulin levels, HbA1c level, and six metabolic markers, in 1,527 models for predicting progression risk.
https://diabetes.acponline.org/archives/2018/12/14/1.htm
14 Dec 2018
Approved drugs for diabetic neuropathy better than placebo, review finds
In addition to approved drugs duloxetine, pregabalin, and tapentadol, some benefits were found with venlafaxine, oxcarbazepine, tricyclic antidepressants, tramadol, and botulinum toxin.
https://diabetes.acponline.org/archives/2017/04/14/2.htm
14 Apr 2017
Liraglutide may offer high-risk patients protection from CV events, death, study finds
The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial, which was funded by Novo Nordisk and the National Institutes of Health, randomized 9,340 patients ages 50 years and older to 1.8 mg of liraglutide per day via injection or placebo in addition to standard care.
https://diabetes.acponline.org/archives/2016/07/15/1.htm
15 Jul 2016
Higher prevalence of complications in young adults diagnosed with type 2 vs. type 1 diabetes
Compared to those with type 1 diabetes, participants with type 2 had a significantly higher age-adjusted prevalence of diabetic kidney disease, retinopathy, peripheral, arterial stiffness, and hypertension by age 21.
https://diabetes.acponline.org/archives/2017/03/10/3.htm
10 Mar 2017
Dapagliflozin associated with lower risk for all-cause mortality in type 2 diabetes regardless of CVD risk, study finds
The population-based retrospective cohort study included 22,124 type 2 diabetes patients from a British national primary care database, 4,444 of whom had taken dapagliflozin.
https://diabetes.acponline.org/archives/2017/03/10/2.htm
10 Mar 2017
Sickle cell trait affects HbA1c's accuracy as a measure of glycemia, study finds
Mean HbA1c was 5.7% in the African-American participants with sickle cell trait and 6.0% in those without, despite similar mean fasting and two-hour glucose values.
https://diabetes.acponline.org/archives/2017/02/10/2.htm
10 Feb 2017
Continuous glucose monitoring associated with lower HbA1c in type 1 diabetes treated with insulin injection
An editorial accompanying the two trials of continuous glucose monitoring stressed that the physicians involved had extensive experience with the technology and noted that the necessary changes in lifestyle and insulin dosing can be variable and complicated.
https://diabetes.acponline.org/archives/2017/02/10/3.htm
10 Feb 2017